// App-Quantinova.ai

: Impact of Multiple Sclerosis Disease Modifying Therapies on Effectiveness of SARS Cov 2 Vaccines A Longitudinal Total Population Study of National Health Service NHS England

Researchers

Presenter

  • Afagh Garjani

Principal Investigators

  • Sameer Patel

  • Graham R Law

  • Dhiren Bharkhada

  • Waqar Rashid

  • Alasdair Coles

  • Nikos Evangelou

Medical Centers

  • Clinical Neurology, Nottingham University Hospitals NHS Trust

  • Mental Health and Clinical Neurosciences Academic Unit, School of Medicine, University of Nottingham

  • Direct Commissioning, National Health Services Arden and Greater East Midlands Commissioning Support Unit

  • School of Health and Social Care, University of Lincoln

  • National Health Services England and National Health Services Improvement Midlands

  • Neurology Department, St George's University Hospitals NHS Foundation Trust

  • Department of Clinical Neurosciences, University of Cambridge, UK

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Multiple Sclerosis

Biomarkers

  • N/A

Drug/Treatment

  • glatiramer

  • Dimethyl fumarate

  • Teriflunomide

  • Natalizumab

  • Ocrelizumab

  • Cladribine

  • Fingolimod

  • Interferon

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved